Radiation, chemo, and immunotherapy before rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has not spread to other parts of the body.
- Your tumor is located within 12 cm of the anal opening.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- Your tumor is stage T3-T4 or has spread to nearby lymph nodes (N+).
- You have not had radiation to the pelvis or certain cancer treatments in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests a new treatment approach for locally advanced rectal cancer that is pMMR/MSS. It combines a short course of radiation before surgery with a drug called ivonescimab and chemotherapy, aiming to improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This study tests a specific “before surgery” treatment (radiation plus chemotherapy), followed by more chemotherapy to improve outcomes in people with certain types of rectal cancer. You might be considered if your cancer is locally advanced but not spread to distant organs.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.